Multicenter Trial for Adults With Partial Seizures
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
To compare seizure frequency in patients with refactory partial seizures (with or without
generalization) who are taking Talampanel versus placebo as an add-on therapy to other
licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in
this group of patients.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries